Business Wire

NY-CONDECO

12.4.2022 14:32:15 CEST | Business Wire | Press release

Share
Employees Want the Best of Both Worlds: New Survey From Condeco Reveals Critical Facets of Hybrid Work That Business Leaders Need to Address

Condeco , a global leader in workspace scheduling software, is today announcing new research that reveals the importance of fostering a workplace that understands and respects employee needs, with hybrid work opportunities at its core. Its findings support the understanding that hybrid capabilities lead to greater employee advocacy and happiness at work and show that when it comes to recommending their company, hybrid workers can be the biggest advocates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005267/en/

Allowing for a better work-life balance was identified as one of the biggest benefits of hybrid working through Condeco’s new research, which shows a direct relationship between employee satisfaction and improved mental and emotional well-being. Significantly, more than a third of workers surveyed reported that a hybrid work model has positively impacted their mental and physical health.

“Everyone wants something different out of work, but we can clearly see that almost no one wants to be back in the office full-time,” said Paul Statham, Condeco’s CEO & Founder. “We all know by now that hybrid models are key to ensuring a healthy work-life balance, but how each employer acts on that realization will determine their employees’ fulfillment with their company. No one is suggesting that the office is obsolete, on the contrary, it remains a vital place for employees to collaborate and engage. Business leaders looking to provide the best of both worlds for their employees must find a way to transform their offices from a place employees have to go to a place they want to go.”

“The need to have the right digital tools in place has emerged as one of the most important things to get right for hybrid working,” continued Lynda Lowe, CMO at Condeco. “But different generations have different definitions of what the ‘right tools’ are. This research clearly shows the biggest barriers to hybrid working and the fact that many employees still don’t feel that their company is using the right tools for hybrid working.”

Condeco polled 1,500 of today’s workers to get a pulse on the attitudes towards hybrid work and how these feelings are impacting businesses’ acclimation to the future of the working world. Key findings include:

Hybrid Workers Are Happy Workers – And in Turn, They’re Your Most Loyal Employees

  • 62% of respondents said they feel satisfied with their current hybrid work schedule – and fostering a work culture that brings happiness helps employers attract and retain top talent.
  • Hybrid workers are employers’ biggest advocates, with 63% saying they would recommend their company as an ideal work destination.
  • Nearly half of those back in their offices full-time would like to be more hybrid, which employers struggling with the ‘Great Resignation’ appear not to be considering.

Hybrid Work Has Had a Positive Impact on Mental Health, But There Is Still Room for Improvement

  • 34% of respondents feel that hybrid working has had a positive impact on their mental and physical health, with only 11% feeling that it has had a negative effect.
  • 69% of hybrid workers agreed that their employer takes into consideration the emotional and mental wellbeing of employees.
  • The number one benefit of hybrid working was a better work-life balance, with the lack of a social environment offered by work being the biggest barrier to remote working.

Tech Is the Backbone of Hybrid Work – Yet Only Half of Today’s Employees Have the Right Tools

  • Businesses have realized the opportunity of hybrid working – 78% of managers believe their business has been streamlined as a result and 80% trust their employees to get their work done.
  • Having the right digital tools was identified as the top need to ensuring hybrid working, but only 51% of employees agree that their company is using the right tools to support flexible work and only 50% of respondents feel their company is open to feedback about their digital tool stack.
  • Companies are grappling with how best to bring employees back to the office on a flexible basis. To ensure collaboration and high productivity, employers must consider their workplace tech as the backbone to their strategy.

As part of Condeco’s broader marketing campaign that addresses today’s cultural shift in business, Condeco is today releasing a new film short that shines light on the generational divide that has emerged out of the pandemic, and light-heartedly cements the importance of having an employer that understands and embraces employee needs. You can see the full broadcast here .

To download Condeco’s full survey, complete with additional statistics and methodology, please visit: https://www.condecosoftware.com/modern-workplace/research/attitudes-to-hybrid-working-report-2022/ .

About Condeco

Condeco is the global leader in enterprise level workspace solutions. Our software is designed to equip everyone with the tools they need for a seamless end to end experience in today’s office. By giving people control over flexible work, we deliver the certainty people need, enable the collaboration teams crave, and facilitate the insights on capacity that employers demand. From visitor management to workspace booking to office optimization, we are trusted by over 2000 of the world’s largest companies to realize their future at work.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye